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ABSTRACT: After more than a year of the COVID-19 pandemic, SARS-CoV-2 infection
rates with newer variants continue to devastate much of the world. Global healthcare systems
are overwhelmed with high positive patient numbers. Silent hypoxia accompanied by rapid
deterioration and some cases with septic shock is responsible for COVID-19 mortality in many
hospitalized patients. There is an urgent need to further understand the relationships and
interplay with human host components during pathogenesis and immune evasion strategies.
Currently, acquired immunity through vaccination or prior infection usually provides sufficient
protection against the emerging variants of SARS-CoV-2 except Omicron variant requiring
recent booster. New strains have shown higher viral loads and greater transmissibility with
more severe disease presentations. Notably, COVID-19 has a peculiar prognosis in severe
patients with iron dysregulation and hypoxia which is still poorly understood. Studies have
shown abnormally low serum iron levels in severe infection but a high iron overload in lung
fibrotic tissue. Data from our in-silico structural analysis of the spike protein sequence along
with host proteolysis processing suggests that the viral spike protein fragment mimics Hepcidin
and is resistant to the major human proteases. This functional spike-derived peptide dubbed
‘Covidin’ thus may be intricately involved with host ferroportin binding and internalization
leading to dysregulated host iron metabolism. Here, we propose the possible role of this
potentially allogenic mimetic hormone corresponding to severe COVID-19 immunopathology
and illustrate that this molecular mimicry is responsible for a major pathway associated with
severe disease status. Furthermore, through 3D molecular modeling and docking followed by
MD simulation validation, we have unraveled the likely role of Covidin in iron dysregulation
in COVID-19 patients. Our meta-analysis suggests the Hepcidin mimetic mechanism is highly
conserved among its host range as well as among all new variants to date including Omicron.
Extensive analysis of current mutations revealed that new variants are becoming alarmingly
more resistant to selective human proteases associated with host defense.

Key points:


The dysregulation of iron homeostasis appears to be a hallmark feature of severe SARSCoV-2 infection



The decreased availability of free iron outside of the cell is protective against many
bacterial infections, but the importance of intracellular iron for SARS-CoV-2 is well
established



In addition to increasing intracellular iron for viral replication, the presence of both host
Hepcidin and its molecular mimic Covidin at high levels will likely result in toxic levels
of intracellular iron (Ferroptosis)



Ferroptosis leads to the release of free radicals which also have a toxic effect on
surrounding cells



SARS-CoV-2 variants are becoming resistant to host proteolysis innate defense
mechanisms.



The Y→N 501 mutation confers site loss of the cathepsin G enzyme susceptibility



An alarming aspect is that loss of lysosomal protease sites on spikes may enable SARSCoV-2 variants to infect macrophages in the future opening the possibility of antibodymediated enhancement of COVID-19

Introduction:
The COVID-19 pandemic is caused by the SARS-CoV-2 virus, which belongs to the
Coronaviridae family. Other members of the family have phylogenetic similarities, including
SARS-CoV, which causes Severe Acute Respiratory Syndrome (SARS), and MERS-CoV,
which causes Middle Eastern Respiratory Syndrome (MERS)[Gupta et al., 2021a]. The clinical
spectrum of COVID-19 infection ranges from asymptomatic to critical illness with typical
fever, malaise, cough, gastrointestinal symptoms, shortness of breath, and myalgias. The mean
incubation period for COVID-19 is currently understood as between 5-12 days [Lauer et al.,
2020] while new variants, such as Delta and Omicron, have even shorter incubation times
[COVID and Team, 2021; Homma et al., 2021; Snell et al., 2021]. Patients who progress to severe
COVID-19 disease develop dyspnea and hypoxia with rapid progression to respiratory failure
and commonly meet the criteria for acute respiratory distress syndrome (ARDS)[Control et al.,
2021]. Severe COVID-19 also leads to multi-organ failure hallmarked by the cytokine release
syndrome characterized by fever, thrombocytopenia, and markedly elevated inflammatory
markers [Chen et al., 2020; Maciorowski et al., 2020; Onder et al., 2020].
A commonality among members in the Coronaviridae family is the viral spike (S) protein, the
principal viral surface glycoprotein responsible for host membrane attachment. The S protein
is a transmembrane trimer in a metastable prefusion conformation that undergoes structural
rearrangement and peptidase processing to fuse the viral membrane with the host cell
membrane [Gupta et al., 2021b]. This protein mediates viral attachment to the host cell surface
receptors and is responsible for the consequent fusion between the viral and host membranes
to enable viral entry [Plante et al., 2021a]. The S protein has two subunits, S1 and S2 (Fig. 5.).
When the S1 subunit binds to a host cell receptor, the interaction causes shedding of the
destabilized S1 subunit and transitions to the S2 subunit that maintains a stable post-fusion
conformation [Wrapp et al., 2020]. In terms of viral attachment mechanisms, it is clear that
both SARS-CoV and SARS-CoV-2 recognize the angiotensin-converting enzyme II (ACE2)
receptor as the host receptor that binds to the S protein[Hoffmann et al., 2020].
Recent studies note a significant similarity between the SARS-CoV-2 spike glycoprotein
cytoplasmic tail region and the amino acid sequence of the Hepcidin protein[Ehsani, 2020].

There is a lacuna of understanding the role of molecular mimicry by an intracellular portion of
spike protein and the soluble human analog Hepcidin. In this context, manipulating host iron
regulation may be a key component in understanding the pathogenesis, lung fibrosis,
hypoxemia, inflammation, and cytokine release syndrome associated with serious COVID-19
infection. The dysregulated iron state in COVID-19 pathogenesis has not been fully explored.
However, there are links to iron and its dysregulation in the paradox of hyperferritinemia[Ruan
et al., 2020] and anemia status[Zhao et al., 2020], which are seen together in COVID-19,
particularly in severely infected patients [Sarode et al., 2021]. This dysregulation and iron
overload causing ferroptosis may explain other symptomatology of COVID-19 pathogenesis
including multi-organ pathology[Jacobs et al., 2020; Yang and Lai, 2020], and explain
neuroprotection by vitamin E, a known ferroptosis blocker[Tavakol and Seifalian, 2021]. Iron
dysregulation has been linked to neurological disturbances including cognitive impairment,
ageusia, and anosmia which are common manifestations of severe COVID-19 disease[Edeas et
al., 2020].
Hepcidin is a liver-derived peptide hormone that is a crucial regulator of systemic iron
homeostasis[Girelli et al., 2021]. Hepcidin was first isolated in the year 2000 as a peptide with
antimicrobial activity and independently described in the literature after being isolated from
both human dialysate ultrafiltrate as well as from urine[Wojciechowska et al., 2021]. Hepcidin
is encoded by the Hepcidin antimicrobial peptide (HAMP) gene and is initially synthesized as
an 84 amino acid pre-pro-Hepcidin. This molecule is then processed to the 60 amino acid proHepcidin, and is ultimately cleaved to a mature C-terminal 25 amino acid active peptide[Leong
and Lönnerdal, 2004]. In 2004, Nemeth et al. described the target site of Hepcidin as
ferroportin[Nemeth and Ganz, 2021]. Ferroportin is an iron exporter on the surface of
absorptive intestinal enterocytes, macrophages, hepatocytes, and placental cells, responsible
for releasing iron into plasma.
Hepcidin-ferroportin homeostasis is central to iron regulation and plays a role in several
disease states. By acting on ferroportin, Hepcidin controls the flow of iron into plasma from
duodenal enterocytes absorbing dietary iron, from macrophages involved in recycling of iron
from senescent erythrocytes, and hepatocytes involved in iron storage. When Hepcidin

concentrations are low, iron enters the blood plasma at a high rate. When Hepcidin
concentrations are high, ferroportin is internalized and iron is trapped in enterocytes,
macrophages, and hepatocytes [Nemeth and Ganz, 2021]. Hepcidin synthesis is regulated at the
transcriptional level by multiple stimuli. HAMP gene expression is upregulated by iron
overload, inflammation, and decreased iron-deficient states, and hypoxia[Agarwal and Yee,
2019]. Iron affects gene expression via BMP/SMAD pathways, while inflammation and IL-6
utilize the JAK/STAT pathway[Varga et al., 2021]. Iron is essential for high load viruses
including SARS-CoV-2, which is inhibited by iron chelators in-vitro[Salaris et al., 2021]. But
excess intracellular iron accumulations lead to apoptosis (ferroptosis) as seen in COVID-19
patient biopsies[Jacobs et al., 2020; Manivannan and Sundaresan, 2021]. The host Hepcidin
protein does not instigate iron accumulation localized near the infection site, in contrast to
patients with severe pneumonitis. Furthermore, hypoxemic hypoxia blocks Hepcidin formation
completely via multiple pathways[Choi et al., 2007].
Host proteases create a hostile environment for pathogens and thus play an important role in
innate immunity. They are also critical for antigenic processing and adaptive immunity. The
variations in the substrate site, as well as protease polymorphisms, alter the processing[Pereira
et al., 2021; Rawat et al., 2013]. A zoonotic pathogen that lacks co-evolutionary history with a
new host needs to modify and adapt through molecular evolution in order to thrive[Plante et
al., 2021b]. SARS-CoV-2 has demonstrated multiple instances of species' jump [Ekstrand et al.,
2021] and the rapid evolution for adapting to the new hosts, for example, the Mink
variant[Bayarri-Olmos et al., 2021]. Another peculiar feature of SARS-CoV-2 is the advent of
convergent mutations, i.e. the same mutations among different lineages[Cherian et al., 2021;
Martin et al., 2021; Zhou et al., 2021]. However, antibody response specificity varies
significantly among individuals and cannot exert a selective pressure specific enough for sitespecific convergent mutations.
This manuscript investigates the mechanism through which SARS-CoV-2 utilizes host
hormone mimicry as demonstrated through protein modeling, docking, and MD simulations.
We found that spike protein degradation by host proteases leads to the release of a Hepcidinlike peptide. We hypothesize that infected cells with surplus viral proteins when ultimately

degraded through various pathways involving proteases can release a Hepcidin mimetic
peptide dubbed Covidin. We hypothesize that a Hepcidin-like overload profile is caused by a
virus-derived Covidin protein which is supported by the clinical data reported from numerous
studies. Furthermore, analysis of the proteolytic fate of the spike protein and release of Covidin
among all the variants reported so far, reveal an important association of mutations with
proteolytic sites.

Methods
Multiple sequence alignment (MSA) of SARS-CoV-2 spike mimetic peptide (Covidin)
with Hepcidin sequence from different mammals. The NCBI databank was used to retrieve
protein sequences from mammals recorded for Hepcidin hormone orthologues structurally
related to SARS-CoV-2. The analysis aimed at investigating the conservation of Hepcidin in
reference sequences vs clinical and environmental strains of SARS-CoV-2 from different
countries (GISAID)[Kalia et al., 2021] using bioinformatics tools. T-COFFEE and PRALINE
software [Bawono and Heringa, 2014; Dereeper et al., 2008] were used for alignment.
Worldwide mutation rates for Covidin peptide. GSAID database global SARS-CoV-2
sequence analysis available from the Nextrain server was used to map mutation rates in the
Hepcidin mimetic region (Covidin) of the spike protein[Hadfield et al., 2018].
Analysis of host protease activity on the SARS-CoV-2 Spike protein. The host protease
specificity and spike protein cleavage site locations were predicted using the iProt-Sub
Server[Song et al., 2019]. The iProt-Sub server employs an algorithm based on specificity
information from the MEROPS database[Rawlings et al., 2016] that has been validated for 38
different proteases from the four major protease families (aspartic, cysteine, metallo-, and
serine) and was used to identify substrate protein cleavage sites for each of the enzymes
examined. The amino acid residue N-terminal to the cleavage site is color-coded by protease
family; the color code assigned with the iProt-Sub server was red for aspartic, yellow for
cysteine, blue for metallo-, and green for serine, with multiples assigned to the highest scoring
family at a given site (Fig.4). iProt-Sub is considered the most advanced server with greater
accuracy and coverage due to its more comprehensive server capabilities and adoption of
machine-learning techniques.
The Procleave server[Li et al., 2020], a more advanced version of iProt-sub, has implemented
a probabilistic model trained with both sequence and structure feature information. The
Procleave database consists of AI trained with 66,441 protein-substrate complexes. The
scoring matrix was used to shortlist affected protease sites. We have analyzed spike protein

sequences of representative isolates from highly prevalent lineages of SARS-CoV-2. Data
were obtained from the NIAID Virus Pathogen Database and Analysis Resource
(ViPR)[Pickett et al., 2012]. The different spike proteins were mapped for polymorphisms and
analyzed by the Procleave server selecting from most of the significant human proteases. The
differences in the scores for all the protease substrate sites analyzed were compared among all
variants. A more than 50% drop in score indicated a difference in the target peptides’ cleaved
or partially cleaved status by specific proteases. Even though the mutants have only a few
substitutions, they have significantly altered protease specificity landscapes (Table 1).
Protein & peptide modeling. For ferroportin protein structures, we first determined if there
are any homologous proteins with known structures. This was attempted using sequence-based
searches on the Protein Data Bank (PDB)[PDBe-KB: a community-driven resource for structural
and functional annotations, 2020]. The search did not yield any feasible homologs with available
3D structures. To circumvent this, a de-novo/fragment modeling approach was performed
using the I-Tasser server [Yang et al., 2015] and the human ferroportin amino acid residue
sequence was uploaded to the server. COACH predictions[Wu et al., 2018] for ligand and metal
ion binding characteristics and OPM servers’ prediction[Lomize et al., 2012] for extracellular
domain orientation were used to predict the binding site for the peptides. Small peptide
modeling for Hepcidin and Covidin was performed using the Phyre2 server[Kelley et al., 2015].
All models were validated and corrected by the FGMD server[Zhang et al., 2011].
Protein-peptide docking. The ClusPro server was selected due to its prior success in
predicting at least one near-native complex within its top 10 predicted interfaces[Kozakov et
al., 2017]. We uploaded our structure files from the I-Tasser and Phyre2 modeling to the
ClusPro server. Once the server had completed its predictions, we then selected the top 30
predicted interfaces to be investigated further. Following the data from the COACH and OPM
servers, the top docking cluster for each peptide showed interactions with the extracellular
domain and blocked the central channel. The top 30 interfaces between the Ferroportin
structure and the peptides showed high similarity with each other in terms of binding
interactions. The top cluster was selected for further investigation. To map out the interactions
in 2D, we used LigPlot+ v.2.2 software[Laskowski and Swindells, 2011], which superimposes

the interactions of the two peptide ligands with ferroportin demonstrating the same binding
core space and interacting residue pairs.
MD simulations of docked complexes. All calculations, simulations, and visualizations for
this work were conducted on a Dell Precision T3430 running Ubuntu Linux version `bionic
beaver` on an Intel Xeon E-2174G processor. All simulation preparations and simulations were
conducted using the Desmond Molecular Dynamics System, with code available from D. E.
Shaw Research, integrated with the Maestro molecular modeling environment provided by
Schrödinger, LLC[Schrodinger, 2020b]. Visualization and trajectory analyses were conducted
using the Maestro GUI interface to Schrodinger using the Simulations interaction diagram
wizard[Schrodinger, 2020a]. As no ferroportin structure is available from Homo sapiens or any
other mammal, the I-TASSER server modeled the structure [Yang et al., 2015]. The topology
of ferroportin in a lipid bilayer membrane was obtained from the Orientations of Proteins in
Membranes database (OPM)[Lomize et al., 2012]. The top model from I-TASSER was preprocessed using Maestro’s ‘Protein Preparation Wizard.’ During pre-processing, all nonprotein crystal artifacts including waters (>3 non-water hydrogen bonds), ions, and any ligands
were removed, and all hydrogens in the model were deleted to minimize mistakes in bond
orders and hydrogen atoms added to all protein residues as warranted. After pre-processing,
the Protein Preparation Wizard noted any overlapping atoms or missing residue side chains.
The errors if any were resolved using Optimization/minimization steps using the OPSL3e force
field. The Maestro System Builder tool was employed to construct a multi-molecular system
for the Molecular Dynamics simulation. This tool primarily performed six tasks to prepare the
modeled system as follows: (1) a water box encompassing the protein docked with either of
the peptides (Hepcidin/Covidin) was created to provide at least a 10 Å buffer for the protein
in all directions, in reference to whole complex spacial dimentions; (2) a lipid bilayer
membrane was placed around the protein according to OPM coordinates utilizing POPC
phospholipid models and extending to the simulation box in the x and y directions; (3) the
system was solvated in a solution of TIP3P water models; (4) 0.1 M NaCl was placed in the
solution to mimic physiological conditions; (5) ions and water molecules placement were
excluded within 3 Å of the protein; and (6) OPLS3e force field parameters were selected for
utilization for both this preparation and all later simulations.

Results and Discussion
Phylogenetic analysis. The Hepcidin mimetic peptide at the C-terminal region of the SARSCoV-2 Spike protein is usually omitted from protein structure determinations because the
second heptad repeat domain destabilizes the spike structure to form a mature fusion protein
with the first heptad domain. Not much is known about the function of this highly conserved
portion of the spike protein in the literature. This homologous peptide is more similar to its
accepted primary sequence in bat and pangolin hosts (Figs 1 &2). The mimicry appears to be
highly conserved among the spectrum of hosts suggesting a functional role in pathogenesis
typical of Coronaviruses (Fig 2). There is a grouping observed among mammals susceptible to
severe SARS-CoV-2 infection (Fig 1). While the peptide present in primates and bats seems
to be more evolved, the similarity between the two groups is noteworthy due to the apparent
evolutionary distance between the two groups of species.
The global mutant distribution shows multiple prevalent mutations in the spike protein. The
mutant/variants of the spike protein are known to have an advantage against detection by
several monoclonal antibodies[Greaney et al., 2021], but variants are primarily neutralized by
original Wuhan strain-based vaccines or previous infection[Bertoglio et al., 2021; Stamatatos et
al., 2021]. Additionally, there is an underlying founder effect at play due to several seeding
infections in each geographical area at the beginning of the pandemic and the reintroduction
of more virulent variants. The appearance of convergent mutations among various distinct
lineages suggests a common selective pressure that is very site-specific. While antibody
specificity dramatically varies from individual to individual, it is not expected to elicit single
amino acid level changes. Compared to mutation rates for the whole spike protein, the Covidin
region is highly conserved (Fig 3). It is to be noted that most of the mutations were for amino
acids positioned on the surface of the structure (Fig 5). The viral S protein displays the highest
degree of genetic variability in the virus genome, however, the region encoding the Covidin
peptide has proven highly conserved among the identified SARS-CoV-2 variants (Fig 3). This
relationship of hepcidin and molecular mimicry of the SARS-CoV-2 Covidin peptide with host
ferroportin may have significant ramifications on iron dysregulation and may be a key to
understanding severe COVID-19 human disease.

Protease site mapping. Upon whole sequence protease site mapping by the most advanced
servers including iProt-Sub and Procleave, the fate of spike in the human body was revealed
to be excessive fragmentation due to proteolysis by various resident human proteases (Fig. 4).
Interestingly, the Covidin peptide was resistant to human proteolytic machinery suggesting
persistence of this peptide post spike degradation in infected individuals and upon
autophagy/apoptosis or necrotic degradation of dead infected cells with surplus unassembled
viral proteins. The Covidin peptide region was 100% conserved in all the major variants
including the recent highly mutated Omicron strain[Karim and Karim, 2021] analyzed (Table
1) and therefore, proteolytic resistance was likewise conserved. There was, however, specific
and repetitive protease site loss by the mutations in the variants (Table1.) (The Omicron
protease map is presented separately in Supplementary table1 because of too many unique
mutations). While the spike protein is heavily glycosylated protecting it from proteases, a few
sites on the protein surface are still vulnerable to proteolysis and were protected by
polymorphisms in the variants. A spacial clustering i.e., the structural proximity of mutations
conferring site loss for proteases from the same cellular/extracellular compartment/location
was observed. (Fig 5).
As there is no evolutionary advantage to 'lethal' strains, the appearance of variants with a more
severe prognosis instead of asymptomaticity, which is more advantageous for unchecked
spread, is perplexing. The mutations have a few unique characteristics such as they seem to be
scattered and there is no hotspot to evade antibody binding though, all are on the surface i.e.
exposed outside protein structure. There is little correlation between the known neutralizing
antibody binding sites and emerging mutations[Cameroni et al., 2021; Chauhan et al., 2021].
The loss of the Meprin A and matrix metallopeptidase protease (MMPs) sites were either at
the RBD or towards the N-terminus of the S1 cleavage site. Meprin A and MMPs are involved
in fibrosis, tissue injury, and inflammation, all of which are hallmarks of severe COVID-19
disease. Meprin A enzymes are expressed to remodel epithelial cells and collagen and to help
in macrophage infiltration to the alveoli sac[Bonnans et al., 2014]. Cross cleavage of such
enzymes might have a detrimental effect on viral potency and RBD integrity. The earliest and
most prevalent mutation of D→G at 614 has been an enigma concerning the mechanism of

benefit to the variant as it causes a site loss to Meprin A subunit-beta. Loss of Thrombin and
Furin cleavage sites are also toward the N-terminal spike region and might help respective
variants with a more stable spike protein.
The site loss for cathepsins is nearby or on the viral fusion domains. These enzymes are
aspartic proteases optimally working at acidic pH and many are present in the lysosome. Such
site loss makes sense to keep viral fusion machinery active in the endosome from where the
nucleocapsid can be delivered to the cytoplasm through viral fusion. The most omnipresent
Y→N 501 mutation confers the site loss of the 'cathepsin G' enzyme which is an inflammationassociated enzyme involved in eliminating intracellular pathogens. The Y→N 501 mutation
has been attributed to enhanced virulence in many lineages with unknown mechanisms
[Callaway, 2021]. Lysosomal enzyme site loss may also be advantageous to the virus as these
proteases are responsible for antigen processing. These polymorphisms should also have
poorer antigen presentation in the variants and could be an immune evasion strategy. Antigen
processing has already been reported to correlate with COVID-19 severity. Genome-wide
association studies (GWAS) have shown the gene ERAP2 associated with one of the high-risk
variants [Lu et al., 2020], which has been shown to affect adaptive immune response by altered
antigen processing[Chen et al., 2016]. This suggests that the variants are becoming hypoimmunogenic and may have more severe disease and not confer much protection against reinfection. Antibody-dependent enhancement (ADE) caused by enhanced viral replication has
been reported for viruses that infect macrophages, including SARS-CoV[Weingartl et al., 2004]
and MERS-CoV[Agrawal et al., 2016] both in vitro and in vivo[Wan et al., 2020]. It has been
reported that there is no macrophage persistence from infection by SARS-CoV-2 and hence no
ADE [García-Nicolás et al., 2021; Hui et al., 2020]. But if the variants are becoming more
resistant to lysosomal proteases including Cathepsin G, then more severe infection observed
in the variants could be attributed to ADE. As these mutations are present on different lineages,
and we have seen many convergent mutations in past with SARS-CoV-2, these strains might
be evolving in the same direction. Such possibilities are alarming since a considerable fraction
of the population now has antibodies against SARS-CoV-2 through infection or vaccination.
ADE was recently observed with the Delta variant with a cross-reactive antibody failing to
neutralize

the

mutant

and

resulting

in

macrophage

infection

through

the

IgG

receptors[Maemura et al., 2021; Yahi et al., 2021]. The recent emergence of the Omicron
strain[Karim and Karim, 2021] which is the most infectious of the lineage is heavily mutated
in the spike protein region and is responsible for a breakthrough as well as reinfections of
SARS-CoV-2 [Pulliam et al., 2021; Wilhelm et al., 2021]. While Omicron varient causes mild
disease it reduces protection from vaccines and prior infections[Cele et al., 2021], and due to
the Omicron-spike protein epitope gap with other varients, the Omicron-specific antibodies
could aggravate ADE in subsequent Delta varient infection which is still in circulation.
Protein modeling, protein-protein docking, and MD simulations. The peptide models of
Covidin were highly similar to Hepcidin (Fig. 6). The docking with modeled ferroportin
showed biochemical conservancies, and the interactions observed also have significant
physiological mimicry of host Hepcidin. The interaction MAP revealed 85% spacial overlap
in the binding site, and Covidin has more interactions with the target ferroportin (Fig. 7). It is
noteworthy that this is a conserved interaction among different hosts due to exponentially
faster turnover of the viral peptide and is expected to become more evolved.
Long MD simulations (100ns) could not reveal how Hepcidin or Covidin promote ferroportin
ubiquitination and degradation, as the system seem to be highly stable for both the complexes
(Figs 8&9). But as seen with the interaction map, the Covidin-ferroportin complex was more
stable than the Hepcidin-ferroportin complex. As both peptide and receptor were modeled, the
confidence in the structure is limited, however, the critically important receptor ferroportin
should be crystallized and structurally characterized with urgency.
Relationship of Iron transport, Hepcidin, and Covidin. Lung fibrosis observed in COVID19 patients and resulting hypoxia is the main reason for mortality in severe cases which can
also be complicated by secondary bacterial and fungal infections[Wang et al., 2020]. COVID19 infection in humans is primarily asymptomatic or exhibiting a mild disease unless it
manifests with the onset of hypoxemia from pneumonitis which may progress to acute
respiratory

distress

syndrome

(ARDS)

with

similarities

to

toxic

shock

syndrome(TSS)[Chambers, 2020]. There is still a lack of understanding as to why some
individuals are asymptomatic, some require low-oxygen supplementation to then recover,

while others rapidly decompensate into ARDS[López-Escobar et al., 2021]. It is possible that
once a threshold is crossed by either uncontrolled hyperinflammation and/or stimulation of the
signaling pathways comodulated by hypoxia and the result is ARDS[Helms et al., 2020]. The
vast quantity of Covidin released from dying lung fibroblasts caused by the SARS-CoV-2 virus
may be a contributing factor (Fig. 10.).
Patients infected with the Delta variant have documented higher viral loads in bronchial
alveolar lavages[Malik et al., 2021]. Similarly, the presentations of those infected with the Delta
variant are described to have fewer co-morbidities and more rapid decompensation than those
with the original Wuhan strain or alpha strain[Twohig et al., 2021]. The virulence-associated
with the Delta strain is due to the higher viral burden, higher particle infectivity, and
hypoantigenicity[Mlcochova et al., 2021]. COVID-19 associated lung fibrosis is not governed
by classic pathways and a deviation has been reported by multiple studies[de Paula et al., 2020].
While Ferritin is shown to be highly expressed in COVID-19 patients due to cytokine storm,
IL-6 induction, or increased release from damaged cells, contrastingly the serum iron and
transferrin levels were both very low[Bellmann-Weiler et al., 2020]. Reduction in transferrin
levels indicates cellular iron accumulation through this carrier and can even activate platelets
(Fig.10.). Under hypoxic conditions, the normal response of the organism is to increase the
number of red blood cells (RBCs), thereby increasing the delivery of oxygen to starved tissues
and organs. During hypoxic conditions, the signaling pathway involving hypoxia-inducible
factors (HIFs) is also activated. HIFs are known to reduce Hepcidin levels thereby increasing
the extracellular iron levels, stimulating erythropoiesis, and boosting active hemoglobin levels
through increased erythropoietin(EPO) release[Liu et al., 2012]. An elaborate histopathological
analysis of a 44-year old victim of SAR-CoV-2-ARDS showed multi-organ ferroptosis
primarily in the lungs[Jacobs et al., 2020]. Sphingosine-1 is one of the markers of severe
COVID-19 [Brondani et al., 2020; de Paula et al., 2020] and is induced by high serum iron or
Ferroptosis [Thayyullathil et al., 2021]. ABO gene loci have been associated with the severity
of COVID-19 [Buti Ferret et al., 2020; Thibord et al., 2021; Zhao et al., 2021], and these same
gene loci have been implicated in iron dysregulation diseases e.g. hemochromatosis[Benyamin
et al., 2014]. Severe COVID-19 is accompanied by hypoxia which strongly reduces Hepcidin
levels through erythropoietin (EPO) hormone[Liu et al., 2012], and such iron dysregulation can

be attributed to Covidin peptide which we have found to be proteolysis resistant against
common and major human proteases and thus can present in very high concentrations once
excess spike protein is degraded in dying/dead infected cells through phagocytosis. Hypoxia
is essential in escalating viral infection, as it induces surface localization of Furin
protease[Arsenault et al., 2012], bypassing the endosomal route of nucleocapsid to plasma
membrane fusion through cell surface spike processing by furin enzyme. Also, SARS-CoV-2
and hypoxia-induced ACE2 overexpression should depress TGF-β and thereby reduce fibrosis,
the opposite of what is observed.
Further, Vitamin D and Mn2+ have shown to be effective in reducing the severity, and in the
case of Vitamin D, reduced mortality has been seen in large trials[Griffin et al., 2021]. However,
the mechanism of action is still not well established. As these agents induce overexpression of
ferroportin, the reduction of ferroptosis and thereby Sphingosine-1 mediated fibrosis could be
a plausible mechanism of action for the observed protection. This can be further coupled with
Hepcidin hormone antagonists like Fursultiamine[Hawula et al., 2019], an FDA-approved
vitamin supplement, or LY2928057[Witcher et al., 2013], a monoclonal antibody in Phase 2
clinical trials to reverse the severe fibrosis and ferroptosis in lung alveoli epithelia. As Covidin
mimics Hepcidin, it should therefore cause ferroportin degradation via the ubiquitin
proteasomal pathway, whereby antagonists alone cannot reverse the intracellular iron overload.
The hypoxia might also be accelerated by reduced erythropoiesis due to low serum iron, rapidly
deteriorating a patient’s condition, and aggravating COVID-19 morbidity. This hypoxia may
be further aggravated based on recent reports of SARS-CoV-2 invading erythropoietic
cells[Shahbaz et al., 2021].
The dysregulation of iron homeostasis appears to be a hallmark of severe SARS-CoV-2
infection. Several studies noted elevated serum ferritin levels correlate to severe disease,
anemia, and elevated Hepcidin levels, and may be helpful as clinical predictors for severe
disease[Taneri et al., 2020; Zhou et al., 2020]. Furthermore, there is a concern that Hepcidin
overexpression could play a role in SARS-CoV-2 infection specifically in those with high-risk
comorbidities[Banchini et al., 2021]. Under infectious pro-inflammatory conditions, the innate
immune system responds with increased host Hepcidin production, ultimately decreasing the

bioavailability of iron. The decreased availability of free iron outside of the cell is protective
against many bacterial infections, but the importance of intracellular iron for SARS-CoV-2 is
well established[Perricone et al., 2020]. In addition to increasing intracellular iron for viral
replication, if both host Hepcidin and its molecular mimic Covidin are at high levels, this will
likely result in toxic levels of intracellular iron(Fig.11). In effect, there is a “Hepcidin
overdose” which leads to an intracellular iron burden that overwhelms host cytoplasmic ferritin
with high levels of iron-mediated free radicals leading to cell death via ferroptosis. Ferroptosis
leads to the release of free radicals which also have a toxic effect on surrounding cells. Iron
chelators have been shown to play a promising protective role in reducing/reversing
fibrosis[Birlutiu et al., 2021; Serrano et al., 2020]. In addition to Covidin’s effect on iron
regulation, a downstream effect of the iron released post ferroptosis in the form of hemin can
activate platelets as has been seen in COVID-19 patients[Pretorius and Kell, 2014; Schmaier,
2020].
Future scope. The effects of COVID-19 infection and the role of Covidin homology need
further investigation to determine its precise role in the inflammatory processes of severe
COVID-19 infection. Ferroportin-Hepcidin/Covidin complex structures need to be
experimentally

characterized.

Iron

chelation

and

Vitamin

D

induced

ferroportin

overexpression during the early stages of infection need to be trialed as prophylactic from the
ferroportin-hypoxia-COVID trifecta. Additional mechanistic studies are warranted to
understand this complex disease and improve patient management. Also, global strain
monitoring is more paramount than ever. Epidemiology of severity, especially in resourcepoor settings is required to quarantine any ‘superbug’ with more virulence or capable of ADE
'in time'. Personalized and more specific quarantine and containment measure guidelines for
close contacts of severe COVID-19 patients might aid in restricting the spread of superbugs,
as we have experienced failures in that regard with the currently dominant Delta variant and
soon to be dominant Omicron. Uninterrupted development of vaccines tailored to the latest
strains to combat variants capable of immune evasion or ADE should be of paramount
importance. Small molecule SARS-CoV-2 essential enzymes inhibitors could also help control
novel strains as functional sites have lower mutation rates than the spike proteins.

CONCLUSION. Our proteolysis, protein modeling, peptide docking, and MD simulation
experiments strongly support a functional biological mimicry by Covidin of the natural host
Hepcidin, an iron homeostatic hormone. Further, this association seems to be highly conserved
within the established primary hosts of SARS-CoV-2, consistent with supporting evidence of
the high iron requirement by relatively large and resource-intensive elevated viral turnover of
SARS-CoV-2. Other hypoxic conditions created by ferroptotic de-epithelization and fibrosis
of lungs fuel COVID-19 severity by modulating proteases such as furin, TMPRSS2, and
increasing infectivity. As in many viral respiratory diseases, the role of the possibly hypoxic
state that ensues during or after viral pathology must be considered. This is where the
relationship between hepcidin, the master regulator of iron hemostasis in the body, and the
pathogenesis of SARS-CoV-2 and its iron-dependent replication limitation must come under
scrutiny.
Thus, early control of ferroptosis or direct countering of Covidin-ferroportin interactions might
provide a key intervention to reduce the mortality and suffering of COVID-19 ARDS patients.
The longer phasing of host iron efflux utilized in SARS-CoV-2 replication can prolong the
rapid replication and escape of the virion particles, thus allowing the possibility of therapeutic
interventions to reduce SARS-CoV-2 induced pathologies.
SARS-CoV-2 variant evolution has led to critical protease resistance in the virus and has
conferred higher infection rates and a more severe disease prognosis. This may have facilitated
the selection of new variants that are hypoimmunogenic in terms of adaptive immunity and
thereby leading to reduced protection against reinfection by variant disease. An alarming
aspect is that loss of lysosomal protease sites on spikes may enable SARS-CoV-2 variants to
infect macrophages in the future opening the possibility of antibody-mediated enhancement in
COVID-19. Therefore, as long as the virus is allowed to spread globally relatively unrestrained,
the danger will persist. With the emergence of new and more infective strains, ADE reported
in the Delta variant, and the immunogen gap increasing between variants calls for universal
treatments. The 100% conserved Covidin peptide sequenced could provide a key to developing
a cure by alleviating the root cause of severe disease that results in mortality.
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Figure legends
Fig.1. Phylogenetic analysis of Hepcidin hormone reveals a grouping among mammals with
severe SARS-CoV-2 infection, while the peptide in primates and bats seems to be more
evolved. Still, the similarity between the two groups is surprising due to the actual species
evolutionary distance between the two.
Fig.2. Multiple sequence alignment of spike fragment homologous to Hepcidin we now call
Covidin with different mammals. The hotter regions (towards the red spectrum) are highly
conserved while colder (towards the blue spectrum) are the least conserved. Hepcidin seems
to be highly conserved among all mammals and has high homology with the Covidin.
Interestingly the Covidin homology is higher for pangolin and bat which are postulated to be
viral reservoirs suggesting an evolutionary advantage conferred by this peptide for viral
pathogenesis.
Fig. 3. Current mutation rates of different regions of the SARS-CoV-2 genome (GSAIDNextstarain). Data from 4298 genomes sampled between Dec 2019 and Aug 2021 shows the
Covidin peptide has 0.0028 average mutational diversity making it highly conserved compared
to 0.2 and 0.05 average mutational diversity for whole-genome and spike protein, respectively.
Mutations are represented by vertical bars with sizes proportional to percent frequencies. (A)
Genome-wide mutation rates, (B) Mutation rates in Spike protein, and (C) Mutation rates in
the Covidin region.
Fig.4. The protease map of Spike protein (N terminal on the left and C terminal on the right).
This analysis suggests that if a spike protein is degraded by human protease, there is a high
probability of releasing Hepcidin like a peptide fragment i.e. Covidin. This spike degradation
could result following normal endosomal degradation of the spike, post nucleocapsid delivery
in the cytoplasm, or necrosis of the dead virus-infected cell with the unassembled surplus
spike. The sequence of the peptide at position 1214-1255 w.r.t. Ref:UniProt ‘P0DTC2’ (Wuhan
isolate) is “N-term-‘WYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCK’-Cterm.”

Fig. 5. Procleave prediction of variation in protease site scores due to mutations in various
variant spike sequences (Table.1) relative to the Wuhan sequence mapped on 3D structure
(PDB ID: 7KJ2). Proteases act as innate immune components by degrading foreign peptides
thus rendering them ineffective. The variant mutations, though mainly on the protein surface,
do not seem to confer much immunological advantage, as only a few seem to improve receptor
binding. Mutations have long been attributed to greater stability and transmissibility of viruses,
in part by enabling the survival of proteases present in the host system.
Fig.6. Schematic representation of Comparative 3D structure of interacting (A) Natural
Hepcidin and (B) Covidin docked at the central pore of ferroportin.
Fig.7 (A): Comparative amino acid interaction map of Hepcidin vs. Covidin with Ferroportin
central pore extracellular domains. The colored interactions are host Hepcidin with Ferroportin
and grayscale are Covidin with ferroportin in the same space. (B) Comparative amino acid
interaction map of Covidin vs. Hepcidin with Ferroportin central pore extracellular domains.
The colored interactions are Covidin with Ferroportin and grayscale are Hepcidin with
ferroportin in the same space. Both Hepcidin and Covidin bind strongly to the central pore
from the extracellular space of a host iron transporter `ferroportin` and the resulting complex
has similar interaction features and binding space as the natural hormone Hepcidin.
Fig.8. MD simulation (100 ns) of natural Hepcidin hormone bound to ferroportin. The docking
was highly stable with negligible deviation from original throughout the simulation and the
OPM predicted membrane topology chosen for simulation was also highly stable.
Fig.9. MD simulation (100 ns) of Covidin viral origin peptide bound to ferroportin. The
docking was highly stable with negligible deviation from the original dock throughout the
simulation, and the OPM predicted membrane topology chosen for simulation was also highly
stable.

Fig.10. Cartoon representation of overlap of hypothetical iron dysregulation by Hepcidin-like
peptide Covidin and the actual clinical picture of COVID-19 patients. The lung fibrosis
observed in COVID-19 patients and resulting hypoxia is the main reason for mortality in severe
cases now seconded by secondary bacterial and fungal infections[Yang and Lai, 2020]. Classic
pathways do not govern COVID-19 associated lung fibrosis and a deviation has been reported
by multiple workers [Rodriguez-Duran et al., 2019]. Ferritin is shown to be highly expressed in
COVID-19 patients due to inflammation mediators such as IL-6 and cytokine storm or
increased release from damaged/ferroptosis cells, contrastingly the serum iron and transferrin
levels are very low. Sphingosine-1 is one of the markers of severe COVID-19 is induced by
high serum iron or ferroptosis. But as severe COVID-19 is accompanied by hypoxia which
strongly reduces Hepcidin levels through erythropoietin (EPO) hormone, such iron
dysregulation can be attributed to Covidin peptide which we have found to be proteolysis
resistant against common and major human proteases and thus can be present in very high
concentrations once excess spike protein is phagocytosed in dying infected cells. Hypoxia is
essential in escalating viral infection, and it induces surface localization of Furin protease
bypassing the endosomal route of nucleocapsid but rather plasma membrane fusion by cell
surface spike processing by furin enzyme. Also, SARS-CoV-2 and hypoxia-induced ACE2
overexpression should repress TGF-β and reduce fibrosis, the opposite of what is observed.
Our proteolysis, protein modeling, peptide docking, and MD simulation experiments strongly
support functional biological mimicry of Covidin with the natural host Hepcidin hormone.
Further, this association seems to be more conserved with the proposed primary hosts of
SARS-CoV-2, supporting evidence of high iron requirement by relatively large and resourceintensive high viral turnover of SARS-CoV-2. Further, Vitamin D and Mn2+ have been
effective in reducing the severity, and in the case of Vit. D, reduced mortality as seen in large
trials. However, the mechanism for which is still not well established. As these agents induce
overexpression of ferroportin, the reduction of ferroptosis and thereby Sphingosine-1 mediated
fibrosis could be a plausible mechanism of action for observed protection. This can be further
coupled with Hepcidin hormone antagonists like Fursultiamine (FDA approved vitamin
supplement) or LY3127804 (monoclonal antibody, Phase2) to reverse the severe fibrosis and
possibly ferroptosis in lung alveoli epithelia. As Hepcidin/Covidin causes ferroportin
degradation by ubiquitin proteasomal pathway, antagonists alone cannot reverse the

intracellular iron overload. Reduced erythropoiesis due to low serum iron might also accelerate
hypoxia, rapidly deteriorating patient condition, and aggravating COVID-19.
Fig.11. Overview of the deciphered relationship of different subsets of COVID-19 pathology
and evolution.
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Key points:


The dysregulation of iron homeostasis appears to be a hallmark feature of severe SARS-CoV-2
infection



The decreased availability of free iron outside of the cell is protective against many bacterial
infections, but the importance of intracellular iron for SARS-CoV-2 is well established



In addition to increasing intracellular iron for viral replication, due to presence of both host
Hepcidin and its molecular mimic Covidin at high levels, this will likely result in toxic levels of
intracellular iron (Ferroptosis)



Ferroptosis leads to the release of free radicals which also have a toxic effect on surrounding
cells



SARS-CoV-2 variants are becoming resistant to host proteolysis innate defense mechanism



Y→N 501 mutation confers the site loss of the `cathepsin G` enzyme



Alarming aspect is that loss of lysosomal protease sites on spikes may enable SARS-CoV-2
variants to infect macrophages in the future opening the possibility of antibody-mediated
enhancement in COVID-19
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Table 1. Prediction of protease site loss due to the amino acid polymorphisms among various
prevalent lineages of SARS-CoV-2
Protease site loss (>50% score dip) due to the change in

SARS‐CoV‐2 strains affected

Mutation

the variants

Amino acid
WHO name

PANGO / lineage

number(s)

Original
Type

Amino acid change Name

cleavage site
† (mutation)

Iota
Epsilon

Beta, Gamma

Gamma

Delta, 20a
Gamma

Eta

B.1.526
B.1.427
B.1.429
B.1.351
B.1.28.1

B.1.28.1

B.1.617.2
B.1.28.1

B.1.525

5

sub

L→F

13

sub

S→I

18

sub

L→F

18 & 21

sub

19
26

52

sub
sub

sub

L→F
T→N
R→T
P→S
Q→R
Q→R

matrix metallopeptidase 2
cathepsin L
cathepsin S
matrix metallopeptidase‐7 & 9

MFVF†LVLL
PLVS†SQCV

QCVN†VLNR

calpain‐2
thrombin

VLNR†TRTQ

plasmin
Furin

RTRT†QLPP

matrix metallopeptidase‐2 & 9

PPAY†TNSF

calpain‐1

TRTQ†LPPA

cathepsin E

SSVL†HSTQ

cathepsin D

TQDL†FLPF

cathepsin S & L

HVSG†TNGT

Alpha

B.1.1.7

69‐70

del

del

Beta

B.1.351

80

sub

D→A

Meprin A subunit beta

TKRF†DNPV

95

sub

T→I

cathepsin L

DGVY†FAST

138

sub

D→Y

Meprin A subunit beta

QFCN†DPFL

Iota, Kappa
Gamma

B.1.526
B.1.617.1
B.1.28.1

cathepsin B, matrix metallopeptidase‐2 & 13 IHVS†GTNG

matrix metallopeptidase‐12 and

NDPF†LDVY

Beta

B.1.351

142

sub

D→G

Beta

B.1.351

144

del

del

calpain‐2

PFLG†VYYH

152

sub

W→C

cathepsin L

SWME†SEFR

Meprin A subunit beta

WMES†EFRV

Meprin A subunit beta

WMES†EFRV

calpain‐2

ESEF†RVYS

Epsilon

B.1.427
B.1.429

Meprin A subunit alpha

Kappa

B.1.617.1

154

sub

E→K

Delta

B.1.617.2

156‐158

Del & Ins

EFR→G

Gamma

B.1.28.1

190

sub

R→S

plasmin

KNLR†EFVF

Beta

B.1.351

215

sub

D→G

Meprin A subunit beta

NLVR†DLPQ

Table 1. Prediction of protease site …. Contd…
SARS‐CoV‐2 strains affected

Protease site loss (>50% score dip) due to the change in the

Mutation

variants

Amino acid
WHO name

PANGO / lineage

number(s)

Original
Type

Amino acid change

Name

cleavage site
† (mutation)

matrix metallopeptidase‐2,9 and Meprin A
Iota

Gamma, Beta

Delta, Epsilon, Kappa, Lambda
Delta
Beta, gamma, Zetra, Eta, Theta

B.1.526

B.1.28.1
B.1.351
B.1.617.2 B.1.427
B.1.429 B.1.617.1
B.1.617.2
B.1.28.1
B.1.351 B.1.525

253

sub

D→G

subunit beta

LTPG†DSSS

caspase‐1

TPGD†SSSG

417

sub

K→N/T

matrix metallopeptidase 3

IAPG†QTGK

452

sub

R→L

matrix metallopeptidase 13

YNYR†YRLF

478

sub

T→K

Meprin A subunit alpha

QAGS†TPCN

484

sub

R→L

Meprin A subunit alpha

YNYR†YRLF

501

sub

Y→N

cathepsin G

QPTY†GVGY

A→D

matrix metallopeptidase‐3

DIAD†TTDA

B.1.1.7 B.1.351
B.1.617.1
Alpha, Beta, gamma, delta, Eta

B.1.617.2
B.1.28.1
B.1.525

Alpha

B.1.1.7

570

sub

All

‐‐‐

614

sub

D→G

Meprin A subunit beta

VLYQ†DVNC

Gamma

B.1.28.1

655

sub

H→Y

Meprin A subunit beta

LIGA†EHVN

Eta

B.1.525

677

sub

Q→H

No change

‐‐

Meprin A subunit beta

SPRR†ARSV

thrombin

NSPR†RARS

B.1.1.7
Alpha, delta, Kappa

B.1.617.1

681

sub

P→R

701

sub

A→V

B.1.617.2
Beta Iota

B.1.351
B.1.526

cathepsin L
cathepsin S

MSLG†AENS

Alpha

B.1.1.7

716

sub

T→I

matrix metallopeptidase‐3

SIAI†PTNF

Eta

B.1.525

888

sub

F→L

cathepsin L

FGAG†AALQ

Delta

B.1.617.1

950

sub

D→N

Meprin A subunit beta

GKLQ†DVVN

Alpha

B.1.1.7

982

sub

S→A

cathepsin D

LSRL†DKVE

Gamma

B.1.28.1

1027

sub

T→I

cathepsin L

ANLA†ATKM

Kappa

B.1.617.1

1071

sub

Q→H

cathepsin K

VPAQ†EKNF

Alpha

B.1.1.7

1118

sub

D→H

Meprin A subunit beta

IITT†DNTF
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Supplementary Table 1. Prediction of protease site loss/gain due to amino acid polymorphisms
among strains from the new omicron (B.1.1.529) lineages of SARS-CoV-2. There are around
30 mutations in the first reported omicron variant which is mutating further at an
unprecedented rate. Also, there is a gain of predicted protease cleavage sites unlike other
lineages, possibly explaining milder infections from omicron. The adjacent mutations thus
could be in response to immunological selective pressure given more clustered mutations
compared to other lineages. Also, there are several structural deviations in spike protein
exposing new sites that need to be modified in order for the virus to resist host proteases.

Mutation

Amino acid

Amino acid

number(s)

Type

67

sub

A→V

69

del

H

70

del

V

95

sub

T→I

change

Protease site loss/gain (>50% score change)
Lost site

Gain site

Cleavage site †
(mutation)

cathepsin B

WFHA†ISGT

cathepsin S

FHAI†HVSG

cathepsin B

HAIH†VSGT

cathepsin L

DGVY†FAST

142

del

G

143

del

V

144

del

Y

145

sub

Y→D

211

del

N

PFLG†VYYH

matrix

TPIN†LVRD

metallopeptidase-2

212

sub

L→I

339

sub

G→D

371

sub

S→L

cathepsin S

SVLY†NSAS

373

sub

S→P

cathepsin L

VLYN†SASF

375

sub

S→F

417

sub

K→N

440

sub

N→K

446

sub

G→S

477

sub

S→N

478

sub

T→K

484

sub

493

meprin beta subunit

matrix
metallopeptidase-8
plasmin
matrix
metallopeptidase-9

LCPF†GEVF

NSAS†FSTF
QTGK†IADY
NSNN†LDSK

cathepsin B

NLDS†KVGG

granzyme A

LDSK†VGGN

Meprin A subunit alpha

QAGS†TPCN

E→A

Meprin A subunit alpha

YNYR†YRLF

sub

Q→R

matrix

496

sub

G→S

metallopeptidase-9

498

sub

Q→R

No change

501

sub

Y→N

cathepsin G

505

sub

Y→H

No change

547

sub

T→K

cathepsin S

NGLT†GTGV

614

sub

D→G

Meprin A subunit beta

VLYQ†DVNC

655

sub

H→Y

Meprin A subunit beta

LIGA†EHVN

679

sub

N→K

meprin alpha subunit

QTQT†NSPR

Meprin A subunit beta

SPRR†ARSV

sub

P→H

thrombin

NSPR†RARS

681

sub
764
796

DPFL†GVYY,

caspase-7, cathepsin B

matrix
N→K

sub

D→Y

metallopeptidase-3

FPLQ†SYGF

QPTY†GVGY

LNRA† LTGI

cathepsin L

GSFC†TQLN

Meprin A subunit beta

PPIK†DFGG

sub
856

N→K

matrix

KFNG†LTVL

metallopeptidase-2

954

sub

Q→H

plasmin

LQDV†VNQN

969

sub

N→K

calpain-1

KQLS†SNFG

981

sub

L→F

granzyme A

ILSR†LDKV

